Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 77,548 | 88,661 | 68,299 | 59,764 | 66,177 |
| Receivables | 13,447 | 3,408 | 3,396 | 3,445 | 3,095 |
| TOTAL | $93,826 | $93,571 | $74,219 | $66,956 | $72,686 |
| Non-Current Assets | |||||
| PPE Net | 339 | 332 | 347 | 372 | 249 |
| Other Non-Current Assets | 152 | 1,666 | 951 | 0 | 0 |
| TOTAL | $491 | $1,998 | $1,298 | $372 | $249 |
| Total Assets | $94,317 | $95,569 | $75,517 | $67,328 | $72,934 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,303 | 3,742 | 3,948 | 4,462 | 3,553 |
| Accrued Expenses | 5,842 | 6,028 | 3,268 | 5,264 | 5,416 |
| TOTAL | $9,304 | $9,986 | $7,466 | $9,726 | $9,141 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | N/A | 172 |
| Other Non-Current Liabilities | 0 | 0 | 21 | 0 | 0 |
| TOTAL | $N/A | $N/A | $21 | $N/A | $N/A |
| Total Liabilities | $9,304 | $9,986 | $7,486 | $9,726 | $9,141 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 23,198 | 23,198 | 21,075 | 21,070 | 17,627 |
| Common Shares | 23 | 23 | 21 | 18 | 18 |
| Retained earnings | -140,121 | -138,174 | -127,039 | -117,892 | -110,102 |
| TOTAL | $85,013 | $85,583 | $68,031 | $57,602 | $63,793 |
| Total Liabilities And Equity | $94,317 | $95,569 | $75,517 | $67,328 | $72,934 |